EE525 the Economic Value of Insulin Glargine 300 U/Ml (Gla-300) in People ≥18 Years of Age with Type 2 Diabetes Mellitus: A Value-Based Economic Model from a U.S. Payer Perspective
Value in Health(2022)
Abstract
Previous real-world evidence (RWE) studies have demonstrated lower healthcare resource utilization (HCRU) in Type II diabetes (T2DM) patients who switched from 1st generation to 2nd generation basal insulin (BI) therapies. This study assessed the value and affordability of Gla-300 in a value-based economic model by leveraging the RWE from a U.S. payer perspective.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined